SY
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study | Clinical infectious diseases | 2025 | 11 | 118 | |||
| Low Trauma Fractures in People with HIV : Longitudinal Time Trends in the Swiss HIV Cohort Study 2009-2022 | Clinical infectious diseases | 2025 | 14 | 38 | |||
| Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2025 | 22 | 0 | |||
| Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV : the Swiss HIV Cohort Study | The Journal of infectious diseases | 2025 | 10 | 39 | |||
| Types of Myocardial Infarction in People With HIV in Switzerland | Open forum infectious diseases | 2025 | 9 | 51 | |||
| Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2025 | 15 | 0 | |||
| Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program : A Data Linkage Study of Claims and Swiss HIV Cohort Study Data | Open forum infectious diseases | 2025 | 10 | 12 | |||
| Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection | HIV medicine | 2025 | 15 | 0 | |||
| Leukocyte count and new-onset diabetes mellitus in people with HIV : A longitudinal study | HIV medicine | 2025 | 16 | 14 | |||
| Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV : A feasibility survey | HIV medicine | 2025 | 13 | 47 | |||
| Prevalence and factors associated with severe fatigue 2 years into the COVID-19 pandemic : a cross-sectional population-based study in Geneva, Switzerland | BMJ open | 2025 | 96 | 179 | |||
| Covid-19 pandemic-related changes in teleworking, emotional exhaustion, and occupational burnout : a cross-sectional analysis of a cohort study | BMC public health | 2025 | 77 | 279 | |||
| Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease : A European Multicenter Mpox Observational Cohort Study (MOSAIC) | Clinical infectious diseases | 2025 | 10 | 32 | |||
| Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design | The Journal of experimental medicine | 2025 | 9 | 81 | |||
| Rituximab‐to‐vaccine interval on SARS‐CoV‐2 immunogenicity in children : The potential role of prior natural infection | Pediatric allergy and immunology | 2024 | 128 | 303 | |||
| Biopsychosocial risk factors for subjective cognitive decline among older adults during the COVID-19 pandemic : a population-based study | Public health | 2024 | 7 | 111 | |||
| External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV | Open forum infectious diseases | 2024 | 11 | 46 | |||
| Time Trends in Causes of Death in People With HIV : Insights From the Swiss HIV Cohort Study | Clinical infectious diseases | 2024 | 9 | 93 | |||
| Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in Switzerland | The Lancet regional health. Europe | 2024 | 7 | 55 | |||
| Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells | Nature medicine | 2024 | 9 | 13 | |||
| Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL'HIV Trial | Open forum infectious diseases | 2024 | 6 | 59 | |||
| Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk | Open forum infectious diseases | 2024 | 5 | 23 | |||
| Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study | BMC infectious diseases | 2024 | 64 | 117 | |||
| Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV | Frontiers in pharmacology | 2024 | 7 | 52 | |||
| Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV | Clinical infectious diseases | 2024 | 5 | 38 | |||
| Cohort profile : the Swiss Mother and Child HIV Cohort Study (MoCHiV) | BMJ open | 2024 | 6 | 11 | |||
| Patient and public involvement in HIV research : a mapping review and development of an online evidence map | Journal of the International AIDS Society | 2024 | 4 | 41 | |||
| Self-reported neurocognitive complaints in the Swiss HIV Cohort Study : a viral genome-wide association study | Brain communications | 2024 | 11 | 26 | |||
| Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities | HIV medicine | 2024 | 6 | 28 | |||
| Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy : the SIMPL'HIV open-label, factorial randomised controlled trial | Swiss medical weekly | 2024 | 14 | 50 | |||
| Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocol | BMC infectious diseases | 2024 | 127 | 253 | |||
| Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study | The Journal of infectious diseases | 2024 | 9 | 27 | |||
| Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy | The Journal of infectious diseases | 2024 | 5 | 36 | |||
| Mental health trajectories among the general population and higher-risk groups following the COVID-19 pandemic in Switzerland, 2021-2023 | Journal of affective disorders | 2024 | 8 | 97 | |||
| Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV | Clinical pharmacology and therapeutics | 2024 | 92 | 216 | |||
| Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3) | The Journal of infectious diseases | 2024 | 521 | 537 | |||
| Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study | Liver international | 2024 | 6 | 45 | |||
| Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies | The Journal of experimental medicine | 2024 | 8 | 64 | |||
| Trends in Mortality in People With HIV From 1999 through 2020 : A Multicohort Collaboration | Clinical infectious diseases | 2024 | 9 | 13 | |||
| Prevalence of and risk factors for suicidal ideation in adolescents during the COVID-19 pandemic : a cross-sectional study | Swiss medical weekly | 2024 | 10 | 26 | |||
| Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy | HIV medicine | 2024 | 15 | 48 | |||
| Impact of the COVID-19 pandemic on children and adolescents: determinants and association with quality of life and mental health—a cross-sectional study | Child and adolescent psychiatry and mental health | 2023 | 179 | 193 | |||
| Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1 | The journal of antimicrobial chemotherapy | 2023 | 101 | 0 | |||
| Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy | Clinical infectious diseases | 2023 | 105 | 143 | |||
| Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort Data | Clinical infectious diseases | 2023 | 117 | 96 | |||
| Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort study | The Lancet regional health. Europe | 2023 | 65 | 19 | |||
| Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | 2023 | 102 | 160 | |||
| Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen | British journal of clinical pharmacology | 2023 | 106 | 103 | |||
| External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older | HIV medicine | 2023 | 97 | 78 | |||
| Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection | Clinical infectious diseases | 2023 | 115 | 0 | |||
| Socioeconomic conditions and children's mental health and quality of life during the COVID-19 pandemic : An intersectional analysis | SSM, population health | 2023 | 160 | 114 | |||
| Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study | AIDS | 2023 | 118 | 55 | |||
| Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection | Nature communications | 2023 | 148 | 73 | |||
| Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort Study | The Journal of infectious diseases | 2023 | 97 | 61 | |||
| Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2) | Open forum infectious diseases | 2023 | 92 | 82 | |||
| A Case of Mpox Reinfection | Clinical infectious diseases | 2023 | 78 | 104 | |||
| Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 compared | The Journal of infectious diseases | 2023 | 118 | 90 | |||
| Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations : A 5-year retrospective analysis of routine programmatic data | Health science reports | 2023 | 98 | 57 | |||
| Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | 2023 | 67 | 98 | |||
| Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study | Clinical infectious diseases | 2023 | 103 | 46 | |||
| Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) | Open forum infectious diseases | 2023 | 141 | 97 | |||
| Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19 | Open forum infectious diseases | 2023 | 129 | 161 | |||
| Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018 | The journal of antimicrobial chemotherapy | 2023 | 148 | 240 | |||
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | 2023 | 93 | 117 | |||
| Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS) | HIV medicine | 2022 | 149 | 147 | |||
| A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits | Molecular biology and evolution | 2022 | 166 | 119 | |||
| Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States | The New England journal of medicine | 2022 | 115 | 0 | |||
| Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals | Frontiers in immunology | 2022 | 258 | 107 | |||
| Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics | Journal of acquired immune deficiency syndromes | 2022 | 189 | 75 | |||
| Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland | BMJ open | 2022 | 234 | 86 | |||
| Determinants of adolescents' Health-Related Quality of Life and psychological distress during the COVID-19 pandemic | PloS one | 2022 | 172 | 211 | |||
| CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2022 | 101 | 98 | |||
| Decreased Levels of SARS-CoV-2 Fusion-Inhibitory Antibodies in the Serum of Aged COVID-19 Patients | Diagnostics | 2022 | 245 | 146 | |||
| Applying mixture model methods to SARS-CoV-2 serosurvey data from Geneva | Epidemics | 2022 | 196 | 136 | |||
| Persistent symptoms after SARS-CoV-2 infection in children: a cross-sectional population-based serological study | BMJ open | 2022 | 119 | 133 | |||
| Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort Study | The journal of antimicrobial chemotherapy | 2022 | 97 | 67 | |||
| A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents | Nature communications | 2022 | 220 | 139 | |||
| A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study | The Journal of infectious diseases | 2022 | 157 | 0 | |||
| Transient elevation of humoral responses against apolipoprotein A-1 following COVID-19 and its association with symptoms persistence | 90th EAS (European Atherosclerosis Society) Congress | 2022 | 94 | 0 | |||
| Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence | European journal of clinical investigation | 2022 | 446 | 159 | |||
| COVID-19-related school disruptions and well-being of children and adolescents in Geneva | Journal of paediatrics and child health | 2022 | 158 | 153 | |||
| Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approach | The Journal of infectious diseases | 2022 | 145 | 2 | |||
| A highly virulent variant of HIV-1 circulating in the Netherlands | Science | 2022 | 199 | 94 | |||
| Detecting Selection in the HIV-1 Genome during Sexual Transmission Events | Viruses | 2022 | 158 | 246 | |||
| Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients | BMC infectious diseases | 2022 | 143 | 81 | |||
| Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS) | HIV medicine | 2022 | 117 | 121 | |||
| Cohort Profile Update: The Swiss HIV Cohort Study (SHCS) | International journal of epidemiology | 2022 | 262 | 0 | |||
| Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial | The Lancet. Gastroenterology & hepatology | 2021 | 848 | 218 | |||
| Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission | HIV Medicine | 2021 | 268 | 0 | |||
| Insights into household transmission of SARS-CoV-2 from a population-based serological survey | Nature Communications | 2021 | 441 | 250 | |||
| Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland | Nature Communications | 2021 | 263 | 191 | |||
| SARS-COV2- infection as a trigger of humoral response against apolipoprotein A-1 | EAS Congress 2021 | 2021 | 383 | 38 | |||
| Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study | Open Forum Infectious Diseases | 2021 | 320 | 185 | |||
| Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link | eLife | 2021 | 176 | 88 | |||
| Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment | Clinical infectious diseases | 2021 | 204 | 139 | |||
| The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort Study | Clinical Infectious Diseases | 2021 | 164 | 0 | |||
| Analytical Evaluation of Visby Medical RT-PCR Portable Device for Rapid Detection of SARS-CoV-2 | Diagnostics | 2021 | 340 | 311 | |||
| Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: A large longitudinal cohort study | Infection Control and Hospital Epidemiology | 2021 | 320 | 222 | |||
| Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance | Clinical Microbiology and Infection | 2021 | 303 | 288 | |||
| Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study | Clinical Microbiology and Infection | 2021 | 410 | 229 | |||
| Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis | Nature communications | 2021 | 85 | 13 | |||
| SARS-CoV-2 N501Y introductions and transmissions in Switzerland from beginning of october 2020 to february 2021-implementation of swiss-wide diagnostic screening and whole genome sequencing | Microorganisms | 2021 | 242 | 272 | |||
| Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity | The journal of antimicrobial chemotherapy | 2021 | 180 | 0 | |||
| Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk group | Clinical Infectious Diseases | 2021 | 201 | 0 | |||
| SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1 | European Journal of Clinical Investigation | 2021 | 421 | 261 | |||
| Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study | The Journal of Infectious Diseases | 2021 | 172 | 0 | |||
| Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study | BMJ Open | 2021 | 292 | 157 | |||
| Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study | The Journal of infectious diseases | 2021 | 107 | 40 | |||
| The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study | Journal of clinical medicine | 2021 | 89 | 98 | |||
| Head-to-head evaluation of five automated SARS-CoV-2 serology immunoassays in various prevalence settings | Journal of Clinical Medicine | 2021 | 343 | 206 | |||
| Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018 | Antiviral therapy | 2020 | 73 | 0 | |||
| Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT) | Emerging Microbes & Infections | 2020 | 465 | 255 | |||
| Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study | Clinical Infectious Diseases | 2020 | 236 | 0 | |||
| Validation of a commercially available SARS-CoV-2 serological immunoassay | Clinical Microbiology and Infection | 2020 | 526 | 337 | |||
| HCV genetic diversity can be used to infer infection recency and time since infection | Viruses | 2020 | 231 | 106 | |||
| Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study | The Lancet | 2020 | 783 | 14 | |||
| Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment | Journal of Acquired Immune Deficiency Syndromes | 2020 | 230 | 0 | |||
| Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV | PLoS biology | 2020 | 100 | 31 | |||
| Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test | European Journal of Clinical Investigation | 2020 | 458 | 429 | |||
| Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial | PLoS medicine | 2020 | 229 | 226 | |||
| Head-to-head accuracy comparison of three commercial COVID-19 IgM/IgG serology rapid tests | Journal of Clinical Medicine | 2020 | 380 | 210 | |||
| Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection | Journal of Viral Hepatitis | 2020 | 428 | 0 | |||
| Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma | PLOS ONE | 2020 | 468 | 342 | |||
| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19) | Clinical Infectious Diseases | 2020 | 497 | 338 | |||
| Phylogenetic cluster analysis identifies virological and behavioral drivers of HIV transmission in MSM | Clinical Infectious Diseases | 2020 | 390 | 12 | |||
| How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? | HIV medicine | 2020 | 119 | 53 | |||
| Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy | Open Forum Infectious Diseases | 2020 | 237 | 131 | |||
| Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART | Nature Communications | 2020 | 263 | 88 | |||
| Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients | Clinical Infectious Diseases | 2020 | 374 | 3 | |||
| Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART | Nature Communications | 2019 | 314 | 158 | |||
| The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the swiss mother and child HIV cohort study | Swiss Medical Weekly | 2019 | 294 | 128 | |||
| Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study | Clinical Microbiology and Infection | 2019 | 259 | 195 | |||
| Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patients | Open Forum Infectious Diseases | 2019 | 304 | 257 | |||
| Comparison of analytical performances of the Roche Cobas 6800 CT/NG assay with the Abbott m2000 Real Time CT/NG assay for detecting Chlamydia trachomatis and Neisseria gonorrhoeae | Journal of Medical Microbiology | 2019 | 568 | 0 | |||
| HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected | Journal of Acquired Immune Deficiency Syndromes | 2019 | 327 | 0 | |||
| Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence | The journal of antimicrobial chemotherapy | 2019 | 85 | 0 | |||
| A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseases | The Journal of Infectious Diseases | 2019 | 355 | 0 | |||
| Why do sub‐Saharan Africans present late for HIV care in Switzerland ? | HIV medicine | 2019 | 92 | 0 | |||
| Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infection | The Journal of Infectious Diseases | 2019 | 304 | 0 | |||
| Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study | Virus Evolution | 2018 | 391 | 113 | |||
| Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule | Clinical infectious diseases | 2018 | 90 | 0 | |||
| Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics | PLOS Pathogens | 2018 | 569 | 254 | |||
| The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysis | Open Forum Infectious Diseases | 2018 | 381 | 231 | |||
| Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity | Molecular Biology and Evolution | 2018 | 506 | 232 | |||
| Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study | HIV Medicine | 2018 | 337 | 132 | |||
| Time to overcome pretreatment HIV drug resistance | The Lancet Infectious Diseases | 2018 | 397 | 230 | |||
| Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant | Journal of clinical virology | 2018 | 452 | 536 | |||
| Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland | HIV Medicine | 2018 | 610 | 0 | |||
| Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons | European heart journal | 2018 | 103 | 0 | |||
| A community outbreak of Legionnaires' disease in Geneva, Switzerland, June to September 2017 | Swiss Medical Weekly | 2018 | 527 | 273 | |||
| Tracing HIV-1 strains that imprint broadly neutralizing antibody responses | Nature | 2018 | 184 | 0 | |||
| Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity | The Journal of experimental medicine | 2018 | 310 | 140 | |||
| Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? | Journal of Antimicrobial Chemotherapy | 2017 | 556 | 0 | |||
| Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma | Journal of Antimicrobial Chemotherapy | 2017 | 487 | 0 | |||
| Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis | eLife | 2017 | 502 | 192 | |||
| Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study | Journal of Antimicrobial Chemotherapy | 2017 | 484 | 2 | |||
| Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships | HIV Medicine | 2017 | 452 | 0 | |||
| The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events | Journal of acquired immune deficiency syndromes | 2016 | 87 | 0 | |||
| Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy : The Swiss HIV Cohort Study | Open forum infectious diseases | 2016 | 87 | 97 | |||
| Large-scale inference of conjunctive Bayesian networks | Bioinformatics | 2016 | 453 | 250 | |||
| Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland | Scientific Reports | 2016 | 1,095 | 293 | |||
| In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid | Drug Metabolism and Disposition | 2016 | 607 | 264 | |||
| HIV-Positive-to-HIV-Positive Liver Transplantation | American journal of transplantation | 2016 | 670 | 436 | |||
| Determinants of HIV-1 broadly neutralizing antibody induction | Nature Medicine | 2016 | 566 | 430 | |||
| Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study | The Journal of Infectious Diseases | 2016 | 423 | 251 | |||
| The global spread of HIV-1 subtype B epidemic | Infection, Genetics and Evolution | 2016 | 465 | 303 | |||
| Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs | Retrovirology | 2016 | 505 | 239 | |||
| Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis | Clinical Infectious Diseases | 2016 | 684 | 1 | |||
| Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1 | Open Forum Infectious Diseases | 2016 | 484 | 212 | |||
| HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study | Clinical Infectious Diseases | 2016 | 520 | 217 | |||
| A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland | Scientific Reports | 2016 | 498 | 210 | |||
| Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review | New microbes and new infections | 2015 | 613 | 1 | |||
| Increases in Condomless Sex in the Swiss HIV Cohort Study | Open forum infectious diseases | 2015 | 91 | 72 | |||
| Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based Algorithms | PLOS ONE | 2015 | 497 | 263 | |||
| Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4] | New microbes and new infections | 2015 | 506 | 0 | |||
| Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study | BMC infectious diseases | 2015 | 105 | 89 | |||
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | 2015 | 706 | 0 | |||
| Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland | AIDS | 2015 | 95 | 0 | |||
| Reasons for late presentation to HIV care in Switzerland | Journal of the International AIDS Society | 2015 | 75 | 49 | |||
| Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2015 | 103 | 36 | |||
| Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report | Lancet. Infectious diseases | 2015 | 712 | 1 | |||
| Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds | PLOS pathogens | 2015 | 604 | 264 | |||
| HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons | BMC gastroenterology | 2015 | 79 | 34 | |||
| Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses | Open Forum Infectious Diseases | 2015 | 451 | 231 | |||
| Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma | The journal of antimicrobial chemotherapy | 2015 | 521 | 1 | |||
| Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality | AIDS | 2015 | 77 | 0 | |||
| Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012 | The Journal of infectious diseases | 2015 | 608 | 0 | |||
| Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study | Journal of Antimicrobial Chemotherapy | 2015 | 448 | 192 | |||
| Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV | International journal of epidemiology | 2014 | 777 | 462 | |||
| Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests | PloS one | 2014 | 663 | 716 | |||
| Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients | AIDS | 2014 | 573 | 0 | |||
| Viral escape in the CNS with multidrug-resistant HIV-1 | Journal of the International AIDS Society | 2014 | 713 | 275 | |||
| Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study | Clinical infectious diseases | 2014 | 725 | 0 | |||
| Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland | American journal of epidemiology | 2014 | 876 | 86 | |||
| Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone | HIV clinical trials | 2014 | 84 | 0 | |||
| Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection | The Journal of infectious diseases | 2013 | 663 | 0 | |||
| The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients | PLoS computational biology | 2013 | 712 | 295 | |||
| La prophylaxie postexposition dans tous ses états | Revue médicale suisse | 2013 | 615 | 0 | |||
| A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure | International journal of antimicrobial agents | 2013 | 641 | 0 | |||
| Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study | PloS one | 2013 | 630 | 607 | |||
| Simple Estimation of Incident HIV Infection Rates in Notification Cohorts Based on Window Periods of Algorithms for Evaluation of Line-Immunoassay Result Patterns | PloS one | 2013 | 631 | 290 | |||
| A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control | eLife | 2013 | 646 | 317 | |||
| Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy | AIDS | 2013 | 522 | 0 | |||
| Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study | The journal of antimicrobial chemotherapy | 2013 | 579 | 414 | |||
| Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid | Journal of acquired immune deficiency syndromes and human retrovirology | 2013 | 602 | 0 | |||
| HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes | The journal of antimicrobial chemotherapy | 2013 | 581 | 276 | |||
| Inferring epidemic contact structure from phylogenetic trees | PLoS computational biology | 2012 | 572 | 258 | |||
| Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection | BMC infectious diseases | 2012 | 575 | 362 | |||
| Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine | PloS one | 2012 | 774 | 362 | |||
| Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens | PloS one | 2012 | 644 | 281 | |||
| Critical Analysis of Rhinovirus RNA Load Quantification by Real-Time Reverse Transcription-PCR | Journal of clinical microbiology | 2012 | 725 | 669 | |||
| Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations | Clinical infectious diseases | 2012 | 1,080 | 341 | |||
| Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients | HIV medicine | 2012 | 725 | 0 | |||
| Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients | PloS one | 2012 | 640 | 254 | |||
| Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections | AIDS | 2012 | 744 | 455 | |||
| Estimating the basic reproductive number from viral sequence data | Molecular biology and evolution | 2012 | 588 | 493 | |||
| Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B | Clinical infectious diseases | 2011 | 595 | 402 | |||
| Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients | Haematologica | 2011 | 1,054 | 651 | |||
| Ageing with HIV : medication use and risk for potential drug-drug interactions | The journal of antimicrobial chemotherapy | 2011 | 60 | 0 | |||
| High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease | BMC infectious diseases | 2011 | 687 | 296 | |||
| Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors | PloS one | 2011 | 610 | 402 | |||
| Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study | Arthritis and rheumatism | 2011 | 880 | 8 | |||
| Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study Group | Clinical infectious diseases | 2011 | 105 | 0 | |||
| Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting | PLOS pathogens | 2011 | 661 | 313 | |||
| Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study | The Journal of infectious diseases | 2011 | 688 | 816 | |||
| A randomized crossover study to compare efavirenz and etravirine treatment | AIDS | 2011 | 105 | 0 | |||
| Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals: the Swiss HIV Cohort Study | Journal of translational medicine | 2011 | 667 | 321 | |||
| The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland | The Journal of infectious diseases | 2011 | 675 | 623 | |||
| Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors | Journal of acquired immune deficiency syndromes | 2011 | 721 | 1,642 | |||
| Clinical relevance of cytomegalovirus viraemia | HIV medicine | 2011 | 659 | 0 | |||
| Cohort profile: the Swiss HIV Cohort study | International journal of epidemiology | 2010 | 555 | 0 | |||
| Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir | AIDS | 2010 | 639 | 0 | |||
| Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland | The Journal of infectious diseases | 2010 | 618 | 0 | |||
| Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load | PLOS pathogens | 2010 | 747 | 522 | |||
| Unusual primary HIV infection with colonic ulcer complicated by hemorrhagic shock: a case report | Journal of medical case reports | 2010 | 746 | 330 | |||
| Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures | Journal of acquired immune deficiency syndromes | 2010 | 637 | 0 | |||
| Impact of newly HIV diagnosed individuals on the transmission of drug resistance | Antiviral therapy | 2009 | 451 | 0 | |||
| High prevalence of non-B HIV-1 subtypes in seamen and their sexual partners in Croatia | Journal of medical virology | 2009 | 631 | 0 | |||
| The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection | AIDS | 2009 | 578 | 0 | |||
| Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control study | Clinical infectious diseases | 2009 | 79 | 0 | |||
| Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach | Retrovirology | 2009 | 639 | 65 | |||
| Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland | Clinical infectious diseases | 2009 | 643 | 0 | |||
| Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir | Clinical infectious diseases | 2008 | 590 | 0 | |||
| Drug resistance in newly HIV diagnosed individuals: transmission rate, clusters and persistence | Antiviral therapy | 2008 | 366 | 0 | |||
| Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey | AIDS | 2007 | 519 | 0 | |||
| Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study | AIDS | 2007 | 592 | 0 | |||
| Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types | Archives of internal medicine | 2007 | 619 | 0 | |||
| Cytomegalovirus quantification in plasma by an automated real-time PCR assay | Journal of clinical virology | 2007 | 663 | 0 | |||
| The trap: professional exposure to human immunodeficiency virus antibody negative blood with high viral load | Archives of internal medicine | 2007 | 493 | 0 | |||
| Increased incidence of sexually transmitted infections in Geneva, Switzerland | Dermatology | 2006 | 736 | 0 | |||
| CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial | Lancet | 2006 | 670 | 0 | |||
| Chronic rhinoviral infection in lung transplant recipients | American journal of respiratory and critical care medicine | 2006 | 689 | 0 | |||
| Detection et quantification des acides nucleiques en infectiologie: utilite, certitudes et limites | Revue médicale suisse | 2005 | 611 | 0 | |||
| HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss | Journal of acquired immune deficiency syndromes | 2005 | 600 | 0 | |||
| Amplicon sequencing and improved detection of human rhinovirus in respiratory samples | Journal of clinical microbiology | 2004 | 621 | 0 | |||
| Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions | AIDS | 2004 | 632 | 0 | |||
| Infrequent transmission of HIV-1 drug-resistant variants | Antiviral therapy | 2004 | 615 | 0 | |||
| Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact | American journal of respiratory and critical care medicine | 2004 | 615 | 0 | |||
| HIV-1 co/super-infection in intravenous drug users | AIDS | 2004 | 600 | 0 | |||
| Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy | Clinical infectious diseases | 2004 | 68 | 0 | |||
| Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20 | AIDS | 2004 | 819 | 0 | |||
| Travel and the spread of HIV-1 genetic variants | Lancet. Infectious diseases | 2003 | 593 | 0 | |||
| A prospective trial of structured treatment interruptions in human immunodeficiency virus infection | Archives of internal medicine | 2003 | 624 | 0 | |||
| Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial | AIDS | 2003 | 620 | 0 | |||
| Drug resistance mutations during structured treatment interruptions | Antiviral therapy | 2003 | 556 | 0 | |||
| A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection | The Journal of infectious diseases | 2002 | 648 | 0 | |||
| A patient with HIV-1 superinfection | The New England journal of medicine | 2002 | 566 | 0 | |||
| Acute HIV infection: impact on the spread of HIV and transmission of drug resistance | AIDS | 2001 | 519 | 0 | |||
| Nosocomial outbreak of multiple bloodborne viral infections | The Journal of infectious diseases | 2001 | 707 | 275 | |||
| Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study | AIDS | 2000 | 534 | 0 | |||
| Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates | AIDS | 2000 | 455 | 0 | |||
| Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection | AIDS | 2000 | 566 | 0 | |||
| Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study | The Journal of infectious diseases | 1999 | 577 | 0 | |||
| Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study | AIDS | 1999 | 570 | 0 | |||
| A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study | AIDS | 1998 | 505 | 0 | |||
| A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and omega-3 fatty acids in HIV-infected patients. Swiss HIV Cohort Study | AIDS | 1998 | 643 | 0 | |||
| Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study | Antiviral therapy | 1998 | 505 | 0 | |||
| Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen | The Journal of experimental medicine | 1998 | 514 | 0 | |||
| A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss HIV Cohort Study | Archives of internal medicine | 1998 | 543 | 0 | |||
| Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy | The Journal of infectious diseases | 1998 | 558 | 0 | |||
| Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants | Journal of virology | 1998 | 566 | 0 | |||
| Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study | AIDS | 1997 | 534 | 0 | |||
| Zidovudine plus didanosine in primary HIV-1 infection | Antiviral therapy | 1997 | 589 | 0 | |||
| Prévalence de la transmission de virus résistant à la zidovudine en Suisse. L'étude suisse de cohorte VIH | Schweizerische medizinische Wochenschrift | 1996 | 564 | 0 | |||
| Combined therapy with zidovudine and L-697,661 in primary HIV infection | AIDS | 1996 | 584 | 0 | |||
| Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients | Antiviral therapy | 1996 | 457 | 0 | |||
| Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group | The Journal of infectious diseases | 1996 | 570 | 0 | |||
| Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine | Journal of acquired immune deficiency syndromes and human retrovirology | 1995 | 625 | 0 | |||
| Response of HIV RNA to didanosine as a predictive marker of survival | AIDS | 1995 | 656 | 0 | |||
| Absence of chronic human immunodeficiency virus infection without seroconversion in intravenous drug users: a prospective and retrospective study | The Journal of infectious diseases | 1991 | 548 | 0 |
